Literature DB >> 25754738

Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells.

Richard Apps1, Zhaojing Meng2, Gregory Q Del Prete3, Jeffrey D Lifson3, Ming Zhou2, Mary Carrington4.   

Abstract

The expression level of HLA class-I proteins is known to influence pathological outcomes: pathogens downregulate HLA to evade host immune responses, host inflammatory reactions upregulate HLA, and differences among people with regard to the steady-state expression levels of HLA associate with disease susceptibility. Yet precise quantification of relative expression levels of the various HLA loci is difficult because of the tremendous polymorphism of HLA. We report relative expression levels of HLA-A, HLA-B, HLA-C, and HLA-E proteins for the specific haplotype A*02:01, B*44:02, C*05:01, which were characterized using two independent methods based on flow cytometry and mass spectrometry. PBLs from normal donors showed that HLA-A and HLA-B proteins are expressed at similar levels, which are 13-18 times higher than HLA-C by flow cytometry and 4-5 times higher than HLA-C by mass spectrometry; these differences may reflect variation in the conformation or location of proteins detected. HLA-E was detected at a level 25 times lower than that of HLA-C by mass spectrometry. Primary CD4(+) T cells infected with HIV in vitro were also studied because HIV downregulates selective HLA types. HLA-A and HLA-B were reduced on HIV-infected cells by a magnitude that varied between cells in an infected culture. Averaging all infected cells from an individual showed HLA-A to be 1-3 times higher and HLA-B to be 2-5 times higher than HLA-C by flow cytometry. These results quantify substantial differences in expression levels of the proteins from different HLA loci, which are very likely physiologically significant on both uninfected and HIV-infected cells.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25754738      PMCID: PMC4390493          DOI: 10.4049/jimmunol.1403234

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression.

Authors:  E M Bennett; J R Bennink; J W Yewdell; F M Brodsky
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

3.  Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold.

Authors:  Mustapha Faroudi; Clemens Utzny; Mariolina Salio; Vincenzo Cerundolo; Martine Guiraud; Sabina Müller; Salvatore Valitutti
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  HLA antibody responses in HLA class I transgenic mice.

Authors:  T Tahara; S Y Yang; R Khan; S Abish; G J Hämmerling; U Hämmerling
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

6.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

7.  Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.

Authors:  T Sasazuki; T Juji; Y Morishima; N Kinukawa; H Kashiwabara; H Inoko; T Yoshida; A Kimura; T Akaza; N Kamikawaji; Y Kodera; F Takaku
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

Review 8.  HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

Authors:  M Campoli; S Ferrone
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

9.  Response to Comment on "Influence of HLA-C expression level on HIV control".

Authors:  Richard Apps; Mary Carrington
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

10.  Influence of HLA-C expression level on HIV control.

Authors:  Richard Apps; Ying Qi; Jonathan M Carlson; Haoyan Chen; Xiaojiang Gao; Rasmi Thomas; Yuko Yuki; Greg Q Del Prete; Philip Goulder; Zabrina L Brumme; Chanson J Brumme; Mina John; Simon Mallal; George Nelson; Ronald Bosch; David Heckerman; Judy L Stein; Kelly A Soderberg; M Anthony Moody; Thomas N Denny; Xue Zeng; Jingyuan Fang; Ashley Moffett; Jeffrey D Lifson; James J Goedert; Susan Buchbinder; Gregory D Kirk; Jacques Fellay; Paul McLaren; Steven G Deeks; Florencia Pereyra; Bruce Walker; Nelson L Michael; Amy Weintrob; Steven Wolinsky; Wilson Liao; Mary Carrington
Journal:  Science       Date:  2013-04-05       Impact factor: 47.728

View more
  73 in total

Review 1.  KIR and HLA under pressure: evidences of coevolution across worldwide populations.

Authors:  Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-06-23       Impact factor: 4.132

2.  Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles.

Authors:  Jouni Vesa; Antoine Chaillon; Gabriel A Wagner; Christy M Anderson; Douglas D Richman; Davey M Smith; Susan J Little
Journal:  AIDS       Date:  2017-05-15       Impact factor: 4.177

Review 3.  Conserved and variable natural killer cell receptors: diverse approaches to viral infections.

Authors:  Leidy Y Bastidas-Legarda; Salim I Khakoo
Journal:  Immunology       Date:  2019-01-17       Impact factor: 7.397

Review 4.  Molecular evolution of elements controlling HLA-C expression: Adaptation to a role as a killer-cell immunoglobulin-like receptor ligand regulating natural killer cell function.

Authors:  Stephen K Anderson
Journal:  HLA       Date:  2018-11       Impact factor: 4.513

5.  A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens.

Authors:  Adán Alpízar; Fabio Marino; Antonio Ramos-Fernández; Manuel Lombardía; Anita Jeko; Florencio Pazos; Alberto Paradela; César Santiago; Albert J R Heck; Miguel Marcilla
Journal:  Mol Cell Proteomics       Date:  2016-12-05       Impact factor: 5.911

Review 6.  Strategies for the measurements of expression levels and half-lives of HLA class I allotypes.

Authors:  Malini Raghavan; Brogan Yarzabek; Anita J Zaitouna; Sujatha Krishnakumar; Daniel S Ramon
Journal:  Hum Immunol       Date:  2019-02-05       Impact factor: 2.850

Review 7.  Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Trends Immunol       Date:  2018-01-31       Impact factor: 16.687

8.  The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Authors:  Alexander Hallner; Elin Bernson; Brwa Ali Hussein; Frida Ewald Sander; Mats Brune; Johan Aurelius; Anna Martner; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Blood       Date:  2019-01-15       Impact factor: 22.113

9.  Identification of trophoblast-specific elements in the HLA-C core promoter.

Authors:  Jenna K Johnson; Paul W Wright; Hongchuan Li; Stephen K Anderson
Journal:  HLA       Date:  2018-10-30       Impact factor: 4.513

10.  Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.

Authors:  Thomas van Stigt Thans; Janet I Akko; Annika Niehrs; Wilfredo F Garcia-Beltran; Laura Richert; Christina M Stürzel; Christopher T Ford; Hui Li; Christina Ochsenbauer; John C Kappes; Beatrice H Hahn; Frank Kirchhoff; Glòria Martrus; Daniel Sauter; Marcus Altfeld; Angelique Hölzemer
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.